There are at least three Phase III clinical trials going on, using Genentech, Inc.'s anti-HER2 monoclonal antibody (MoAB). Two of them have publicly available protocols:
There is a third such trial, in which patients can apply once per month to a clinical trials company for entry of their name into a lottery program on a computer; those who win get Genentech's anti-HER2 medicine. The only information available on the World Wide Web about this trial is that which has been posted by the University of Alabama. Oddly, that information says that the "endpoint" (investigational purpose) of the trial is "clinical and laboratory safety" -- a seeming makeweight.
Actually, there are several trials listed at Alabama, all of which seem to be this same lottery. They are: